Biomarker alterations with metronomic use of low-dose zoledronic acid for breast cancer patients with bone metastases and potential clinical significance

By Zhao Xinmin  

Breast Cancer Research and Treatment, Vol. 124, Iss. 3, 2010-12 ,pp. : 733-743

Springer Publishing Company

Access to resources Recommend Favorite

Nail alterations as a surrogate marker for the efficacy of low-dose metronomic chemotherapy

By            

Oncology Letters, Vol. 5, Iss. 4, 2013-01 ,pp. : 1123-1128

Spandidos Publications

Access to resources Recommend Favorite

UKT-04 trial of continuous metronomic low-dose chemotherapy with methotrexate and cyclophosphamide for recurrent glioblastoma

By Herrlinger Ulrich   Rieger Johannes   Steinbach Joachim   Nägele Thomas   Dichgans Johannes   Weller Michael  

Journal of Neuro-Oncology, Vol. 71, Iss. 3, 2005-02 ,pp. : 295-299

Springer Publishing Company

Access to resources Recommend Favorite

Paclitaxel-containing High-dose Chemotherapy in High-risk Breast Cancer Patients

By Greinix Hildegard T.   Linkesch Werner   Seifert Manfred   Kubista Ernst   Czerwenka Klaus   Elahi Fariborz   Zielinski Christoph   Hoecker Paul   Steger Günther   Schulenburg Axel   Neumeister Geralt   Rabitsch Werner   Jakesz Raimund   Kalhs Peter  

Acta Oncologica, Vol. 39, Iss. 1, 2000-04 ,pp. : 47-52

Informa Healthcare

Access to resources Recommend Favorite

Antiangiogenic properties of metronomic chemotherapy in breast cancer

By Tonini Giuseppe   Schiavon Gaia   Silletta Marianna   Vincenzi Bruno   Santini Daniele  

Future Oncology, Vol. 3, Iss. 2, 2007-04 ,pp. : 183-190

Future Medicine

Access to resources Recommend Favorite